4.6 Article

The biology of combination immunotherapy in recurrent metastatic head and neck cancer

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.biocel.2021.106002

关键词

Head and neck cancer; Immunotherapy; Immune escape; Immunotherapy combination

资金

  1. National Natural Science Foundation of China [82073370, 82003310]

向作者/读者索取更多资源

The development of immune checkpoint inhibitors has revolutionized treatment for head and neck cancer, but patients often exhibit primary resistance to immunotherapy. Ongoing trials are exploring combinations of immunotherapy with other interventions to improve treatment outcomes. As novel strategies are leveraged, the significance of immunotherapy in recurrent/metastatic head and neck cancer is being further revealed.
Preclinical data suggest that head and neck cancer is an intrinsically immunosuppressive disease with abnormal inflammatory components in the tumor microenvironment. The development of immune checkpoint inhibitors, which are monoclonal antibodies capable of inhibiting immune suppressive signals to prime anticancer immunity, has revolutionized the therapeutic landscape in recurrent/metastatic head and neck cancer. However, patients with head and neck cancer present primary resistance to immunotherapy. Many ongoing trials include combinations of immunotherapy with different therapeutic interventions, aiming to improve response rates and overall survival. As novel therapy strategies are leveraged, the significance of immunotherapy in recurrent/ metastatic head and neck cancer continues to be revealed. This review aims to summarize combinational immunotherapy in head and neck cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据